单克隆抗体
家族性高胆固醇血症
医学
抗体
免疫学
单克隆
内科学
胆固醇
作者
M. Reijman,D. Meeike Kusters,Albert Wiegman
标识
DOI:10.1080/14712598.2024.2330948
摘要
Introduction Heterozygous familial hypercholesterolemia (HeFH) is a common genetic disorder caused by pathogenic variants in the LDL-C metabolism. Lifelong exposure to elevated LDL-C levels leads to a high risk of premature cardiovascular disease. To reduce that risk, children with HeFH should be identified and treated with lipid-lowering therapy. The cornerstone consists of statins and ezetimibe, but not in all patients this lowers the LDL-C levels to treatment targets. For these patients, more intensive lipid-lowering therapy is needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI